TABLE 1.

Key Model Parameters

Survival Hazard Ratios	Base Case	Lower	Upper	PSA Distribution	Source
Second-line PFS hazard ratios vs. LEN-DEX
CFZ-LEN-DEX	0.69	0.53	0.91	LogNormal	Network meta-analysis
ELO-LEN-DEX	0.70	0.56	1.00	LogNormal	Network meta-analysis
IX-LEN-DEX	0.74	0.65	1.19	LogNormal	Network meta-analysis
DAR-LEN-DEXa	0.37	0.27	0.52	LogNormal	Network meta-analysis
DAR-BOR-DEXa	0.39	0.28	0.53	LogNormal	Network meta-analysis
Third-line PFS hazard ratios vs. LEN-DEX
BOR-DEX	0.93	0.58	2.04	LogNormal	Network meta-analysis
CFZ-LEN-DEX	0.69	0.54	0.87	LogNormal	Network meta-analysis
ELO-LEN-DEX	0.70	0.49	0.87	LogNormal	Network meta-analysis
IX-LEN-DEX	0.74	0.40	0.84	LogNormal	Network meta-analysis
PAN-BOR-DEX	0.59	0.31	1.10	LogNormal	Network meta-analysis
DAR-LEN-DEXa	0.37	0.27	0.52	LogNormal	Network meta-analysis
DAR-BOR-DEXa	0.39	0.28	0.53	LogNormal	Network meta-analysis
Hazard ratio for OS vs. PFS	0.41	0.31	0.58	LogNormal	24
Quality of Life	Base Case	Lower	Upper	PSA Distribution	Source
Second-line health state utilities
Progression-free, on treatment	0.82	0.78	0.88	Beta	Data on fileb
Progression-free, off treatment	0.84	0.82	0.97	Beta	Data on fileb
Progressed disease	0.65	0.62	0.74	Beta	Data on fileb
Third-line health state utilities
Progression-free, on treatment	0.65	0.52	0.78	Beta	25
Progression-free, off treatment	0.72	0.58	0.86	Beta	37
Progressed disease	0.61	0.49	0.73	Beta	25
Adverse event disutility	0.08	0.07	0.08	Beta	25
Costs	Base Case	Lower	Upper	PSA Distribution	Source
Drug acquisition and administration costs,c $
Bortezomib 3.5 mg vial	1,503.00	1,202.40	1,803.60	Normal	RED BOOK
Bortezomib administration	111.42	89.14	133.70	Normal	CPT 96409
Carfilzomib 60 mg vial	1,971.50	1,577.20	2,365.80	Normal	RED BOOK
Carfilzomib administration	209.24	167.39	251.09	Normal	CPT 96360, 96361, 96413
Dexamethasone per mg	0.32	0.26	0.39	Normal	RED BOOK
Elotuzumab 300 mg vial	1,776.00	1,420.80	2,131.20	Normal	RED BOOK
Elotuzumab 400 mg vial	2,368.00	1,894.40	2,841.60	Normal	RED BOOK
Elotuzumab administration	227.87	182.30	273.44	Normal	CPT 96413, 96415, 96417
Ixazomib capsule	3,006.00	2,404.80	3,607.20	Normal	RED BOOK
Lenalidomide capsule	552.98	442.38	663.58	Normal	RED BOOK
Panobinostat capsule	1,222.22	977.78	1,466.67	Normal	RED BOOK
Daratumumab 400 mg vial	1,850.40	1,480.32	2,220.48	Normal	RED BOOK
Daratumumab 100 mg vial	462.60	370.08	555.12	Normal	RED BOOK
Daratumumab administration	399.83	319.86	479.80	Normal	CPT 96413, 96415, 96417
Health State Cost per Week	Progression-Free AE Prophylaxis, $			Progressed Disease Treatment, $
LEN-DEX	22.00			427.45
CFZ-LEN-DEX	104.73			367.30
ELO-LEN-DEX	85.37			369.26
IX-LEN-DEX	85.26			377.05
PAN-BOR-DEX	39.16			337.41
DAR-LEN-DEX	49.45			273.54
DAR-BOR-DEX	90.71			283.94

^aDAR hazard ratios were assessed for a general population and were assumed to be equivalent in second- and third-line settings.

^bAmgen. Data provided in response to ICER data request. QOL/Utility Data from ASPIRE Cost Effectiveness Model. February 22, 2016.

^cCosts assessed March 2016.

BOR = bortezomib; CFZ = carfilzomib; CPT = Current Procedural Terminology; DAR = daratumumab; DEX = dexamethasone; ELO = elotuzumab; IX = ixazomib; LEN = lenalidomide; OS = overall survival; PAN = panobinostat; PFS = progression-free survival; PSA = probabilistic sensitivity analysis.